Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. International most cancers statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 international locations. CA Most cancers J Clin. 2021;71(3):209–49.
Clancy E. ACS report exhibits prostate most cancers on the rise, cervical most cancers on the decline. Renal Urol Information. 2023. https://doi.org/10.3322/caac.21763.
Hasan Mujahid M, Upadhyay TK, Upadhye V, Sharangi AB, Saeed M. Phytocompound identification of aqueous Zingiber officinale rhizome (ZOME) extract reveals antiproliferative and reactive oxygen species mediated apoptotic induction inside cervical most cancers cells: an in vitro and in silico strategy. J Biomol Struct Dyn. 2023;12:1–28.
Cao Z, Liu J. Micro organism and bacterial derivatives as drug carriers for most cancers remedy. J Management Launch. 2020;10(326):396–407.
Wu L, Bao F, Li L, Yin X, Hua Z. Bacterially mediated drug supply and therapeutics: methods and developments. Adv Drug Deliv Rev. 2022;1(187):114363.
Fan JY, Huang Y, Li Y, Muluh TA, Fu SZ, Wu JB. Micro organism in most cancers remedy: a brand new era of weapons. Most cancers Med. 2022;11(23):4457–68.
Hossen S, Hossain MK, Basher MK, Mia MN, Rahman MT, Uddin MJ. Good nanocarrier-based drug supply programs for most cancers remedy and toxicity research: a overview. J Adv Res. 2019;1(15):1–8.
Chen J, Ning C, Zhou Z, Yu P, Zhu Y, Tan G, Mao C. Nanomaterials as photothermal therapeutic brokers. Prog Mater Sci. 2019;1(99):1–26.
Zhao X, Xie N, Zhang H, Zhou W, Ding J. Bacterial drug supply programs for most cancers remedy: “Why” and “How”. Pharmaceutics. 2023;15(9):2214.
Krick EL, Sorenmo KU, Rankin SC, Cheong I, Kobrin B, Thornton Ok, Kinzler KW, Vogelstein B, Zhou S, Diaz LA. Analysis of Clostridium novyi–NT spores in canines with naturally occurring tumors. Am J Vet Res. 2012;73(1):112–8.
Wang L, Wang Q, Tian X, Shi X. Studying from Clostridium novyi-NT: tips on how to defeat most cancers. J Most cancers Res Ther. 2018;14(Suppl 1):S1-6.
Mi Z, Feng ZC, Li C, Yang X, Ma MT, Rong PF. Salmonella-mediated most cancers remedy: an revolutionary therapeutic technique. J Most cancers. 2019;10(20):4765.
Kasinskas RW, Forbes NS. Salmonella typhimurium particularly chemotax and proliferate in heterogeneous tumor tissue in vitro. Biotechnol Bioeng. 2006;94(4):710–21.
Kucerova P, Cervinkova M. Spontaneous regression of tumour and the position of microbial an infection–potentialities for most cancers therapy. Anticancer Medicine. 2016;27(4):269.
Chen W, Wang Y, Qin M, Zhang X, Zhang Z, Solar X, Gu Z. Micro organism-driven hypoxia concentrating on for mixed biotherapy and photothermal remedy. ACS Nano. 2018;12(6):5995–6005.
Toso JF, Gill VJ, Hwu P, Marincola FM, Restifo NP, Schwartzentruber DJ, Sherry RM, Topalian SL, Yang JC, Inventory F, Freezer LJ. Section I research of the intravenous administration of attenuated Salmonella typhimurium to sufferers with metastatic melanoma. J Clin Oncol. 2002;20(1):142–52.
Mercado-Lubo R, Zhang Y, Zhao L, Rossi Ok, Wu X, Zou Y, Castillo A, Leonard J, Bortell R, Greiner DL, Shultz LD. A Salmonella nanoparticle mimic overcomes multidrug resistance in tumours. Nat Commun. 2016;7(1):12225.
Felgner S, Kocijancic D, Frahm M, Heise U, Rohde M, Zimmermann Ok, Falk C, Erhardt M, Weiss S. Engineered Salmonella enterica serovar Typhimurium overcomes limitations of anti-bacterial immunity in bacteria-mediated tumor remedy. Oncoimmunology. 2018;7(2): e1382791.
Fritz SE, Henson MS, Greengard E, Winter AL, Stuebner KM, Yoon U, Wilk VL, Borgatti A, Augustin LB, Modiano JF, Saltzman DA. A section I scientific research to guage security of orally administered, genetically engineered Salmonella enterica serovar Typhimurium for canine osteosarcoma. Vet Med Sci. 2016;2(3):179–90.
Dang LH, Bettegowda C, Huso DL, Kinzler KW, Vogelstein B. Mixture bacteriolytic remedy for the therapy of experimental tumors. Proc Natl Acad Sci. 2001;98(26):15155–60.
Chowdhury S, Castro S, Coker C, Hinchliffe TE, Arpaia N, Danino T. Programmable micro organism induce sturdy tumor regression and systemic antitumor immunity. Nat Med. 2019;25(7):1057–63.
Zhou S, Gravekamp C, Bermudes D, Liu Ok. Tumour-targeting micro organism engineered to struggle most cancers. Nat Rev Most cancers. 2018;18(12):727–43.
Forbes NS. Engineering the right (bacterial) most cancers remedy. Nat Rev Most cancers. 2010;10(11):785–94.
Katuri J, Ma X, Stanton MM, Sánchez S. Designing micro-and nanoswimmers for particular functions. Acc Chem Res. 2017;50(1):2–11.
Zhuang J, Sitti M. Chemotaxis of bio-hybrid a number of bacteria-driven microswimmers. Sci Rep. 2016;6(1):32135.
Zhuang J, Wright Carlsen R, Sitti M. pH-taxis of biohybrid microsystems. Sci Rep. 2015;5(1):11403.
Kefayat A, Ghahremani F, Motaghi H, Rostami S, Mehrgardi MA. Alive attenuated Salmonella as a cargo shuttle for sensible carrying of gold nanoparticles to tumour hypoxic areas. J Drug Goal. 2019;27(3):315–24.
Felfoul O, Mohammadi M, Taherkhani S, De Lanauze D, Zhong XuY, Loghin D, Essa S, Jancik S, Houle D, Lafleur M, Gaboury L. Magneto-aerotactic micro organism ship drug-containing nanoliposomes to tumour hypoxic areas. Nat Nanotechnol. 2016;11(11):941–7.
Takahashi M, Sukowati EW, Nomura S, Kato A, Mizuseki Ok, Watanabe Y, Mukai H. Influence of tumoral construction and bacterial species on progress and biodistribution of dwell bacterial therapeutics in xenografted tumours. J Drug Goal. 2023;31(2):194–205.
Fu L, He Q, Lu X, Hu L, Qiang H, Pei P. Floor engineering on micro organism for tumor immunotherapy: methods and views. Adv Funct Mater. 2024. https://doi.org/10.1002/adfm.202405304.
Montanaro J, Inic-Kanada A, Ladurner A, Stein E, Belij S, Bintner N, Schlacher S, Schuerer N, Mayr UB, Lubitz W, Leisch N. Escherichia coli Nissle 1917 bacterial ghosts retain essential floor properties and categorical chlamydial antigen: an imaging research of a supply system for the ocular floor. Drug Des Dev Ther. 2015;21:3741–54.
Langemann T, Koller VJ, Muhammad A, Kudela P, Mayr UB, Lubitz W. The bacterial ghost platform system: manufacturing and functions. Bioeng Bugs. 2010;1(5):326–36.
Henrich B, Lubitz W, Plapp R. Lysis of Escherichia coli by induction of cloned ϕX174 genes. Mol Gen Genet MGG. 1982;185:493–7.
Bläsi U, Linke RP, Lubitz W. Proof for membrane-bound oligomerization of bacteriophage ϕ X174 lysis protein-E. J Biol Chem. 1989;264(8):4552–8.
Witte A, Bläsi U, Halfmann G, Szostak M, Wanner G, Lubitz W. PhiX174 protein E-mediated lysis of Escherichia coli. Biochimie. 1990;72(2–3):191–200.
Witte A, Wanner G, Sulzner M, Lubitz W. Dynamics of PhiX174 protein E-mediated lysis of Escherichia coli. Arch Microbiol. 1992;157:381–8.
Tabrizi CA, Walcher P, Mayr UB, Stiedl T, Binder M, McGrath J, Lubitz W. Bacterial ghosts–organic particles as supply programs for antigens, nucleic acids and medicines. Curr Opin Biotechnol. 2004;15(6):530–7.
Huter V, Szostak MP, Gampfer J, Prethaler S, Wanner G, Gabor F, Lubitz W. Bacterial ghosts as drug provider and concentrating on autos. J Management Launch. 1999;61(1–2):51–63.
Haslberger AG, Kohl G, Felnerova D, Mayr UB, Fürst-Ladani S, Lubitz W. Activation, stimulation and uptake of bacterial ghosts in antigen presenting cells. J Biotechnol. 2000;83(1–2):57–66.
Chen Z, Liu Y, Yu Y, Yang S, Feng J, Zhu Y, Huang W, Qin B, Guan X, He Z, Solar M. Micro-to-nano oncolytic microbial system shifts from tumor killing to tumor draining lymph nodes remolding for enhanced immunotherapy. Adv Mater. 2023;16:2306488.
Paukner S, Kohl G, Lubitz W. Bacterial ghosts as novel superior drug supply programs: antiproliferative exercise of loaded doxorubicin in human Caco-2 cells. J Management Launch. 2004;94(1):63–74.
Stein E, Inic-Kanada A, Belij S, Montanaro J, Bintner N, Schlacher S, Mayr UB, Lubitz W, Stojanovic M, Najdenski H, Barisani-Asenbauer T. In vitro and in vivo uptake research of Escherichia coli Nissle 1917 bacterial ghosts: cell-based supply system to focus on ocular floor ailments. Make investments Ophthalmol Vis Sci. 2013;54(9):6326–33.
Koller VJ, Dirsch VM, Beres H, Donath O, Reznicek G, Lubitz W, Kudela P. Modulation of bacterial ghosts–induced nitric oxide manufacturing in macrophages by bacterial ghost-delivered resveratrol. FEBS J. 2013;280(5):1214–25.
Wang C, Zhong L, Xu J, Zhuang Q, Gong F, Chen X, Tao H, Hu C, Huang F, Yang N, Li J. Oncolytic mineralized micro organism as potent regionally administered immunotherapeutics. Nat Biomed Eng. 2024;21:1–8.
Adler HI, Fisher WD, Cohen A, Hardigree AA. Miniature Escherichia coli cells poor in DNA. Proc Natl Acad Sci. 1967;57(2):321–6.
Di Ventura B, Sourjik V. Self-organized partitioning of dynamically localized proteins in bacterial cell division. Mol Syst Biol. 2011;7(1):457.
Khachatourians GG, Clark DJ, Adler HI, Hardigree AA. Cell progress and division in Escherichia coli: a typical genetic management concerned in cell division and minicell formation. J Bacteriol. 1973;116(1):226–9.
Inselburg J. Replication of colicin E1 plasmid DNA in minicells from a novel replication initiation web site. Proc Natl Acad Sci. 1974;71(6):2256–9.
MacDiarmid JA, Amaro-Mugridge NB, Madrid-Weiss J, Sedliarou I, Wetzel S, Kochar Ok, Brahmbhatt VN, Phillips L, Pattison ST, Petti C, Stillman B. Sequential therapy of drug-resistant tumors with focused minicells containing siRNA or a cytotoxic drug. Nat Biotechnol. 2009;27(7):643–51.
Mujahid MH, Upadhyay TK, Upadhye VJ. Focused identification of antibacterial phytocompounds from plant extracts in opposition to multidrug-resistant micro organism: a scientific overview.
Kudela P, Koller VJ, Lubitz W. Bacterial ghosts (BGs)—superior antigen and drug supply system. Vaccine. 2010;28(36):5760–7.
Gao J, Chu D, Wang Z. Cell membrane-formed nanovesicles for disease-targeted supply. J Management Launch. 2016;28(224):208–16.
Gao J, Dong X, Su Y, Wang Z. Human neutrophil membrane-derived nanovesicles as a drug supply platform for improved remedy of infectious ailments. Acta Biomater. 2021;15(123):354–63.
Gao J, Dong X, Wang Z. Era, purification and engineering of extracellular vesicles and their biomedical functions. Strategies. 2020;1(177):114–25.
Wang S, Gao J, Li M, Wang L, Wang Z. A facile strategy for improvement of a vaccine manufactured from bacterial double-layered membrane vesicles (DMVs). Biomaterials. 2018;1(187):28–38.
Wang S, Gao J, Wang Z. Outer membrane vesicles for vaccination and focused drug supply. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2019;11(2): e1523.
Toyofuku M, Nomura N, Eberl L. Varieties and origins of bacterial membrane vesicles. Nat Rev Microbiol. 2019;17(1):13–24.
Gerritzen MJ, Martens DE, Wijffels RH, van der Pol L, Stork M. Bioengineering bacterial outer membrane vesicles as vaccine platform. Biotechnol Adv. 2017;35(5):565–74.
Hu R, Liu H, Wang M, Li J, Lin H, Liang M, Gao Y, Yang M. An OMV-based nanovaccine confers security and safety in opposition to pathogenic Escherichia coli by way of each humoral and predominantly Th1 immune responses in poultry. Nanomaterials. 2020;10(11):2293.
Kulp A, Kuehn MJ. Organic capabilities and biogenesis of secreted bacterial outer membrane vesicles. Annu Rev Microbiol. 2010;13(64):163–84.
Mujahid MH, Upadhyay TK, Khan F, Pandey P, Park MN, Sharangi AB, Saeed M, Upadhye VJ, Kim B. Metallic and metallic oxide-derived nanohybrid as a device for biomedical functions. Biomed Pharmacother. 2022;1(155):113791.
Lee EY, Choi DS, Kim KP, Gho YS. Proteomics in gram-negative bacterial outer membrane vesicles. Mass Spectrom Rev. 2008;27(6):535–55.
Biller SJ, Schubotz F, Roggensack SE, Thompson AW, Summons RE, Chisholm SW. Bacterial vesicles in marine ecosystems. Science. 2014;343(6167):183–6.
Schertzer JW, Whiteley M. A bilayer-couple mannequin of bacterial outer membrane vesicle biogenesis. MBio. 2012;3(2):10–128.
Kohl P, Zingl FG, Eichmann TO, Schild S. Isolation of outer membrane vesicles together with their quantitative and qualitative analyses. In: Sikora A, editor. Vibrio cholerae: strategies and protocols. New York: Humana Press; 2018. p. 117–34.
Alzahrani H, Winter J, Boocock D, De Girolamo L, Forsythe SJ. Characterization of outer membrane vesicles from a neonatal meningitic pressure of Cronobacter sakazakii. FEMS Microbiol Lett. 2015;362(12): fnv085.
Badamchi A, Bahrami F, Tasbiti AH, Yari S, Shafiei M, Shahcheraghi F, Siadat SD. Immuno-proteomics evaluation between OMV of vaccine and dominant wild kind strains of Bordetella pertussis in Iran. Iran J Microbiol. 2020;12(2):77.
Schmitt S, Prokisch H, Schlunck T, Camp DG, Ahting U, Waizenegger T, Scharfe C, Meitinger T, Imhof A, Neupert W, Oefner PJ. Proteome evaluation of mitochondrial outer membrane from Neurospora crassa. Proteomics. 2006;6(1):72–80.
McBroom AJ, Kuehn MJ. Launch of outer membrane vesicles by Gram-negative micro organism is a novel envelope stress response. Mol Microbiol. 2007;63(2):545–58.
Eddy JL, Gielda LM, Caulfield AJ, Rangel SM, Lathem WW. Manufacturing of outer membrane vesicles by the plague pathogen Yersinia pestis. PLoS ONE. 2014;9(9): e107002.
Kim OY, Choi SJ, Jang SC, Park KS, Kim SR, Choi JP, Lim JH, Lee SW, Park J, Di Vizio D, Lötvall J. Bacterial protoplast-derived nanovesicles as vaccine supply system in opposition to bacterial an infection. Nano Lett. 2015;15(1):266–74.
Kim OY, Dinh NT, Park HT, Choi SJ, Hong Ok, Gho YS. Bacterial protoplast-derived nanovesicles for tumor focused supply of chemotherapeutics. Biomaterials. 2017;1(113):68–79.
Kuerban Ok, Gao X, Zhang H, Liu J, Dong M, Wu L, Ye R, Feng M, Ye L. Doxorubicin-loaded bacterial outer-membrane vesicles exert enhanced anti-tumor efficacy in non-small-cell lung most cancers. Acta Pharm Sin B. 2020;10(8):1534–48.
Zhang D, Qin X, Wu T, Qiao Q, Music Q, Zhang Z. Extracellular vesicles primarily based self-grown gold nanopopcorn for combinatorial chemo-photothermal remedy. Biomaterials. 2019;1(197):220–8.
Gao J, Wang S, Dong X, Wang Z. RGD-expressed bacterial membrane-derived nanovesicles improve most cancers remedy by way of a number of tumorous concentrating on. Theranostics. 2021;11(7):3301.
Brown L, Wolf JM, Prados-Rosales R, Casadevall A. By way of the wall: extracellular vesicles in Gram-positive micro organism, mycobacteria and fungi. Nat Rev Microbiol. 2015;13(10):620–30.
Liu Y, Defourny KA, Smid EJ, Abee T. Gram-positive bacterial extracellular vesicles and their affect on well being and illness. Entrance Microbiol. 2018;9(9):1502.
Kim JH, Lee J, Park J, Gho YS. Gram-negative and Gram-positive bacterial extracellular vesicles. Semin Cell Dev Biol. 2015;40:97–104.
Toyofuku M, Cárcamo-Oyarce G, Yamamoto T, Eisenstein F, Hsiao CC, Kurosawa M, Gademann Ok, Pilhofer M, Nomura N, Eberl L. Prophage-triggered membrane vesicle formation by way of peptidoglycan injury in Bacillus subtilis. Nat Commun. 2017;8(1):481.
Marsollier L, Brodin P, Jackson M, Korduláková J, Tafelmeyer P, Carbonnelle E, Aubry J, Milon G, Legras P, André JP, Leroy C. Influence of Mycobacterium ulcerans biofilm on transmissibility to ecological niches and Buruli ulcer pathogenesis. PLoS Pathog. 2007;3(5): e62.
Klieve AV, Yokoyama MT, Forster RJ, Ouwerkerk D, Bain PA, Mawhinney EL. Naturally occurring DNA switch system related to membrane vesicles in cellulolytic Ruminococcus spp. of ruminal origin. Appl Environ Microbiol. 2005;71(8):4248–53.
Tzipilevich E, Habusha M, Ben-Yehuda S. Acquisition of phage sensitivity by micro organism by way of trade of phage receptors. Cell. 2017;168(1):186–99.
Rodriguez GM, Prados-Rosales R. Capabilities and significance of mycobacterial extracellular vesicles. Appl Microbiol Biotechnol. 2016;100:3887–92.
Lee J, Lee EY, Kim SH, Kim DK, Park KS, Kim KP, Kim YK, Roh TY, Gho YS. Staphylococcus aureus extracellular vesicles carry biologically lively β-lactamase. Antimicrob Brokers Chemother. 2013;57(6):2589–95.
Olaya-Abril A, Prados-Rosales R, McConnell MJ, Martín-Peña R, González-Reyes JA, Jiménez-Munguía I, Gómez-Gascón L, Fernández J, Luque-García JL, García-Lidón C, Estévez H. Characterization of protecting extracellular membrane-derived vesicles produced by Streptococcus pneumoniae. J Proteomics. 2014;25(106):46–60.
Lee WH, Choi HI, Hong SW, Kim KS, Gho YS, Jeon SG. Vaccination with Klebsiella pneumoniae-derived extracellular vesicles protects in opposition to bacteria-induced lethality by way of each humoral and mobile immunity. Exp Mol Med. 2015;47(9): e183.
Eisenbach M. Bacterial chemotaxis. eLS. 2001. https://doi.org/10.1038/npg.els.0001251.
Sitti M. Voyage of the microrobots. Nature. 2009;458(7242):1121–2.
Sitti M. Microscale and nanoscale robotics programs [grand challenges of robotics]. IEEE Robotic Autom Magazine. 2007;14(1):53–60.
Diller E, Sitti M. Micro-scale cell robotics. Discovered Traits® Robotic. 2013;2(3):143–259.
Vikram Singh A, Sitti M. Focused drug supply and imaging utilizing cell milli/microrobots: a promising future in direction of theranostic pharmaceutical design. Curr Pharm Des. 2016;22(11):1418–28.
Carlsen RW, Sitti M. Bio-hybrid cell-based actuators for microsystems. Small. 2014;10(19):3831–51.
Kim D, Liu A, Diller E, Sitti M. Chemotactic steering of micro organism propelled microbeads. Biomed Microdevice. 2012;14:1009–17.
Jo SD, Ku SH, Gained YY, Kim SH, Kwon IC. Focused nanotheranostics for future personalised medication: latest progress in most cancers remedy. Theranostics. 2016;6(9):1362.
Au JL, Abbiati RA, Wientjes MG, Lu Z. Goal web site supply and residence of nanomedicines: software of quantitative programs pharmacology. Pharmacol Rev. 2019;71(2):157–69.
Mujahid MH, Upadhyay TK, Upadhye VJ, Mathad PS. Antioxidant, antimicrobial, antidiabetic, antiglycation, and biocompatibility potential of Aqueous Zingiber officinale Rhizome (AZOME) Extract.
Stauber JM, Qian EA, Han Y, Rheingold AL, Král P, Fujita D, Spokoyny AM. An organometallic technique for assembling atomically exact hybrid nanomaterials. J Am Chem Soc. 2019;142(1):327–34.
Ling D, Lee N, Hyeon T. Chemical synthesis and meeting of uniformly sized iron oxide nanoparticles for medical functions. Acc Chem Res. 2015;48(5):1276–85.
Das P, Fatehbasharzad P, Colombo M, Fiandra L, Prosperi D. Multifunctional magnetic gold nanomaterials for most cancers. Traits Biotechnol. 2019;37(9):995–1010.
Zhu D, Roy S, Liu Z, Weller H, Parak WJ, Feliu N. Remotely managed opening of supply autos and launch of cargo by exterior triggers. Adv Drug Deliv Rev. 2019;1(138):117–32.
Chen L, Zhou L, Wang C, Han Y, Lu Y, Liu J, Hu X, Yao T, Lin Y, Liang S, Shi S. Tumor-targeted drug and CpG supply system for phototherapy and docetaxel-enhanced immunotherapy with polarization towards M1-type macrophages on triple unfavorable breast cancers. Adv Mater. 2019;31(52):1904997.
Cun X, Chen J, Li M, He X, Tang X, Guo R, Deng M, Li M, Zhang Z, He Q. Tumor-associated fibroblast-targeted regulation and deep tumor supply of chemotherapeutic medication with a multifunctional size-switchable nanoparticle. ACS Appl Mater Interfaces. 2019;11(43):39545–59.
Cartmell T, Mitchell D, Lamond FJ, Laburn HP. Route of administration differentially impacts fevers induced by Gram-negative and Gram-positive pyrogens in rabbits. Exp Physiol. 2002;87(3):391–9.
Cortes-Perez NG, Lefèvre F, Corthier G, Adel-Affected person Ok, Langella P, Bermúdez-Humarán LG. Affect of the route of immunization and the character of the bacterial vector on immunogenicity of mucosal vaccines primarily based on lactic acid micro organism. Vaccine. 2007;25(36):6581–8.
Crull Ok, Bumann D, Weiss S. Affect of an infection route and virulence elements on colonization of stable tumors by Salmonella enterica serovar Typhimurium. FEMS Immunol Med Microbiol. 2011;62(1):75–83.
Zhao M, Yang M, Li XM, Jiang P, Baranov E, Li S, Xu M, Penman S, Hoffman RM. Tumor-targeting bacterial remedy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc Natl Acad Sci. 2005;102(3):755–60.
Rosenberg GA. Neurological ailments in relation to the blood–mind barrier. J Cereb Blood Move Metab. 2012;32(7):1139–51.
Van Sorge NM, Doran KS. Protection on the border: the blood–mind barrier versus bacterial foreigners. Future Microbiol. 2012;7(3):383–94.
Zwagerman NT, Friedlander RM, Monaco EA III. Intratumoral Clostridium novyi as a possible therapy for stable necrotic mind tumors. Neurosurgery. 2014;75(6):N17–8.
Lee CH. Engineering micro organism towards tumor concentrating on for most cancers therapy: present state and views. Appl Microbiol Biotechnol. 2012;93:517–23.
Liu Y, Zhou M, Luo D, Wang L, Hong Y, Yang Y, Sha Y. Micro organism-mediated in vivo supply of quantum dots into stable tumor. Biochem Biophys Res Commun. 2012;425(4):769–74.
Ganai S, Arenas RB, Sauer JP, Bentley B, Forbes NS. In tumors Salmonella migrate away from vasculature towards the transition zone and induce apoptosis. Most cancers Gene Ther. 2011;18(7):457–66.
Loeffler M, Le’Negrate G, Krajewska M, Reed JC. Inhibition of tumor progress utilizing Salmonella expressing Fas ligand. J Natl Most cancers Inst. 2008;100(15):1113–6.
Yam C, Zhao M, Hayashi Ok, Ma H, Kishimoto H, McElroy M, Bouvet M, Hoffman RM. Monotherapy with a tumor-targeting mutant of S. typhimurium inhibits liver metastasis in a mouse mannequin of pancreatic most cancers. J Surg Res. 2010;164(2):248–55.
Sant S, Tao SL, Fisher OZ, Xu Q, Peppas NA, Khademhosseini A. Microfabrication applied sciences for oral drug supply. Adv Drug Deliv Rev. 2012;64(6):496–507.
Sastry SV, Nyshadham JR, Repair JA. Latest technological advances in oral drug supply—a overview. Pharm Sci Technol At present. 2000;3(4):138–45.
Devriendt B, De Geest BG, Goddeeris BM, Cox E. Crossing the barrier: concentrating on epithelial receptors for enhanced oral vaccine supply. J Management Launch. 2012;160(3):431–9.
Correia-Pinto JF, Csaba N, Alonso MJ. Vaccine supply carriers: insights and future views. Int J Pharm. 2013;440(1):27–38.
Urbanska AM, Karagiannis ED, Au AS, Dai SY, Mozafari M, Prakash S. What’s subsequent for gastrointestinal issues: no needles? J Management Launch. 2016;10(221):48–61.
Berlec A, Ravnikar M, Štrukelj B. Lactic acid micro organism as oral supply programs for biomolecules. Die Pharm Int J Pharm Sci. 2012;67(11):891–8.
Hanson ML, Hixon JA, Li W, Felber BK, Anver MR, Stewart CA, Janelsins BM, Datta SK, Shen W, McLean MH, Durum SK. Oral supply of IL-27 recombinant micro organism attenuates immune colitis in mice. Gastroenterology. 2014;146(1):210–21.
Robert S, Gysemans C, Takiishi T, Korf H, Spagnuolo I, Sebastiani G, Van Huynegem Ok, Steidler L, Caluwaerts S, Demetter P, Wasserfall CH. Oral supply of glutamic acid decarboxylase (GAD)-65 and IL10 by Lactococcus lactis reverses diabetes in recent-onset NOD mice. Diabetes. 2014;63(8):2876–87.
Guo S, Yan W, McDonough SP, Lin N, Wu KJ, He H, Xiang H, Yang M, Moreira MA, Chang YF. The recombinant Lactococcus lactis oral vaccine induces safety in opposition to C. difficile spore problem in a mouse mannequin. Vaccine. 2015;33(13):1586–95.
Ahmed B, Loos M, Vanrompay D, Cox E. Oral immunization with Lactococcus lactis-expressing EspB induces protecting immune responses in opposition to Escherichia coli O157: H7 in a murine mannequin of colonization. Vaccine. 2014;32(31):3909–16.
Wei P, Yang Y, Liu Z, Huang J, Gong Y, Solar H. Oral Bifidobacterium longum expressing alpha-melanocyte-stimulating hormone to struggle experimental colitis. Drug Deliv. 2016;23(6):2058–64.
Takei S, Omoto C, Kitagawa Ok, Morishita N, Katayama T, Shigemura Ok, Fujisawa M, Kawabata M, Hotta H, Shirakawa T. Oral administration of genetically modified Bifidobacterium displaying HCV-NS3 multi-epitope fusion protein may induce an HCV-NS3-specific systemic immune response in mice. Vaccine. 2014;32(25):3066–74.
Yu Z, Huang Z, Sao C, Huang Y, Zhang F, Yang J, Lian J, Zeng Z, Luo W, Zeng W, Deng Q. Bifidobacterium as an oral supply provider of interleukin-12 for the therapy of Coxsackie virus B3-induced myocarditis within the Balb/c mice. Int Immunopharmacol. 2012;12(1):125–30.
Ning JF, Zhu W, Xu JP, Zheng CY, Meng XL. Oral supply of DNA vaccine encoding VP28 in opposition to white spot syndrome virus in crayfish by attenuated Salmonella typhimurium. Vaccine. 2009;27(7):1127–35.
Chen G, Wei DP, Jia LJ, Tang B, Shu L, Zhang Ok, Xu Y, Gao J, Huang XF, Jiang WH, Hu QG. Oral supply of tumor-targeting Salmonella displays promising therapeutic efficacy and low toxicity. Most cancers Sci. 2009;100(12):2437–43.
Grillot-Courvalin C, Goussard S, Courvalin P, Silva A, Bodyak N, Vaze M, Sauer N, Laroux FS, Harborth J, Xiang S, Li CJ. Improvement of a therapeutic RNAi supply system utilizing nonpathogenic micro organism expressing inv and hly: transkingdom RNA interference (tkRNAi). Inhuman Gene Remedy. 2009;20(6):670–670.
Ivory Ok, Chambers SJ, Pin C, Prieto E, Arques JL, Nicoletti C. Oral supply of Lactobacillus casei Shirota modifies allergen-induced immune responses in allergic rhinitis. Clin Exp Allergy. 2008;38(8):1282–9.
Huq T, Khan A, Khan RA, Riedl B, Lacroix M. Encapsulation of probiotic micro organism in biopolymeric system. Crit Rev Meals Sci Nutr. 2013;53(9):909–16.
Sohail A, Turner MS, Coombes A, Bostrom T, Bhandari B. Survivability of probiotics encapsulated in alginate gel microbeads utilizing a novel impinging aerosols technique. Int J Meals Microbiol. 2011;145(1):162–8.
Urbanska AM, Bhathena J, Prakash S. Stay encapsulated Lactobacillus acidophilus cells in yogurt for therapeutic oral supply: preparation and in vitro evaluation of alginate–chitosan microcapsules. Can J Physiol Pharmacol. 2007;85(9):884–93.
Jiang T, Singh B, Maharjan S, Li HS, Kang SK, Bok JD, Cho CS, Choi YJ. Oral supply of probiotic expressing M cell homing peptide conjugated BmpB vaccine encapsulated into alginate/chitosan/alginate microcapsules. Eur J Pharm Biopharm. 2014;88(3):768–77.
Mei L, He F, Zhou RQ, Wu CD, Liang R, Xie R, Ju XJ, Wang W, Chu LY. Novel intestinal-targeted Ca-alginate-based provider for pH-responsive safety and launch of lactic acid micro organism. ACS Appl Mater Interfaces. 2014;6(8):5962–70.
Cook dinner MT, Tzortzis G, Khutoryanskiy VV, Charalampopoulos D. Layer-by-layer coating of alginate matrices with chitosan–alginate for the improved survival and focused supply of probiotic micro organism after oral administration. J Mater Chem B. 2013;1(1):52–60.
Lin J, Yu W, Liu X, Xie H, Wang W, Ma X. In vitro and in vivo characterization of alginate-chitosan-alginate synthetic microcapsules for therapeutic oral supply of dwell bacterial cells. J Biosci Bioeng. 2008;105(6):660–5.
Danino T, Prindle A, Kwong GA, Skalak M, Li H, Allen Ok, Hasty J, Bhatia SN. Programmable probiotics for detection of most cancers in urine. Scie Transl Med. 2015;7(289):289ra84.
Bermudes D, Low B, Pawelek J. Tumor-targeted Salmonella: extremely selective supply vectors. In: Habib NA, editor. Most cancers gene remedy previous achievements and future challenges. New York: Springer; 2002. p. 57–63.
Paton AW, Morona R, Paton JC. Bioengineered microbes in illness remedy. Traits Mol Med. 2012;18(7):417–25.
Ciabattini A, Pettini E, Andersen P, Pozzi G, Medaglini D. Main activation of antigen-specific naive CD4+ and CD8+ T cells following intranasal vaccination with recombinant micro organism. Infect Immun. 2008;76(12):5817–25.
Ciabattini A, Giomarelli B, Parigi R, Chiavolini D, Pettini E, Aricò B, Giuliani MM, Santini L, Medaglini D, Pozzi G. Intranasal immunization of mice with recombinant Streptococcus gordonii expressing NadA of Neisseria meningitidis induces systemic bactericidal antibodies and native IgA. Vaccine. 2008;26(33):4244–50.
Izumo T, Maekawa T, Ida M, Noguchi A, Kitagawa Y, Shibata H, Yasui H, Kiso Y. Impact of intranasal administration of Lactobacillus pentosus S-PT84 on influenza virus an infection in mice. Int Immunopharmacol. 2010;10(9):1101–6.
Kotnik T, Rems L, Tarek M, Miklavčič D. Membrane electroporation and electropermeabilization: mechanisms and fashions. Annu Rev Biophys. 2019;6(48):63–91.
Zoaby N, Shainsky-Roitman J, Badarneh S, Abumanhal H, Leshansky A, Yaron S, Schroeder A. Autonomous bacterial nanoswimmers goal most cancers. J Management Launch. 2017;10(257):68–75.
Xie S, Zhang P, Zhang Z, Liu Y, Chen M, Li S, Li X. Bacterial navigation for tumor concentrating on and photothermally-triggered bacterial ghost transformation for spatiotemporal drug launch. Acta Biomater. 2021;1(131):172–84.
Nguyen VH, Kim HS, Ha JM, Hong Y, Choy HE, Min JJ. Genetically engineered Salmonella typhimurium as an imageable therapeutic probe for most cancers. Can Res. 2010;70(1):18–23.
Chou CK, Hung JY, Liu JC, Chen CT, Hung MC. An attenuated Salmonella oral DNA vaccine prevents the expansion of hepatocellular carcinoma and colon most cancers that categorical α-fetoprotein. Most cancers Gene Ther. 2006;13(8):746–52.
Yoon W, Park YC, Kim J, Chae YS, Byeon JH, Min SH, Park S, Yoo Y, Park YK, Kim BM. Software of genetically engineered Salmonella typhimurium for interferon-gamma–induced remedy in opposition to melanoma. Eur J Most cancers. 2017;1(70):48–61.
Din MO, Danino T, Prindle A, Skalak M, Selimkhanov J, Allen Ok, Julio E, Atolia E, Tsimring LS, Bhatia SN, Hasty J. Synchronized cycles of bacterial lysis for in vivo supply. Nature. 2016;536(7614):81–5.
Nguyen DH, Chong A, Hong Y, Min JJ. Bioengineering of micro organism for most cancers immunotherapy. Nat Commun. 2023;14(1):3553.
Xing J, Yin T, Li S, Xu T, Ma A, Chen Z, Luo Y, Lai Z, Lv Y, Pan H, Liang R. Focused most cancers remedy: sequential magneto-actuated and optics-triggered biomicrorobots for focused most cancers remedy. Adv Funct Mater. 2021;31(11):2170074.
Deng X, Yang W, Shao Z, Zhao Y. Genetically modified micro organism for focused phototherapy of tumor. Biomaterials. 2021;1(272):120809.
Min JJ, Nguyen VH, Kim HJ, Hong Y, Choy HE. Quantitative bioluminescence imaging of tumor-targeting micro organism in dwelling animals. Nat Protoc. 2008;3(4):629–36.
Uebe R, Schüler D. Magnetosome biogenesis in magnetotactic micro organism. Nat Rev Microbiol. 2016;14(10):621–37.
Mowday AM, Copp JN, Syddall SP, Dubois LJ, Wang J, Lieuwes NG, Biemans R, Ashoorzadeh A, Abbattista MR, Williams EM, Guise CP. E. coli nitroreductase NfsA is a reporter gene for non-invasive PET imaging in most cancers gene remedy functions. Theranostics. 2020;10(23):10548.
Wang W, Music J, Yu W, Chen M, Li G, Chen J, Chen L, Yu L, Chen Y. Engineering photothermal and H2S-producing dwelling nanomedicine by bacteria-enabled self-mineralization. Adv Funct Mater. 2024. https://doi.org/10.1002/adfm.202400929.
Felgner S, Frahm M, Kocijancic D, Rohde M, Eckweiler D, Bielecka A, Bueno E, Cava F, Abraham WR, Curtiss R III, Häussler S. aroA-deficient Salmonella enterica serovar Typhimurium is greater than a metabolically attenuated mutant. MBio. 2016;7(5):10–128.
Paster E, Ryu WS. The thermal impulse response of Escherichia coli. Proc Natl Acad Sci. 2008;105(14):5373–7.
Zhang Q, Zeng Y, Zhao Y, Peng X, Ren E, Liu G. Bio-hybrid magnetic robots: from bioengineering to focused remedy. Bioengineering. 2024;11(4):311.
Nauts HC, Swift WE, Coley BL. The therapy of malignant tumors by bacterial toxins as developed by the late William B. Coley, MD, reviewed within the mild of recent analysis. Most cancers Res. 1946;6(4):205–16.
Chen F, Zang Z, Chen Z, Cui L, Chang Z, Ma A, Yin T, Liang R, Han Y, Wu Z, Zheng M. Nanophotosensitizer-engineered Salmonella micro organism with hypoxia concentrating on and photothermal-assisted mutual bioaccumulation for stable tumor remedy. Biomaterials. 2019;1(214):119226.
Chen Q, Bai H, Wu W, Huang G, Li Y, Wu M, Tang G, Ping Y. Bioengineering bacterial vesicle-coated polymeric nanomedicine for enhanced most cancers immunotherapy and metastasis prevention. Nano Lett. 2019;20(1):11–21.
Li F, Zhu P, Zheng B, Lu Z, Fang C, Fu Y, Li X. A personalized biohybrid presenting cascade responses to tumor microenvironment. Adv Mater. 2024;9:2404901.
Chen W, Wang Y, Qin M, Zhang X, Zhang Z, Solar X, Gu Z. Micro organism-driven hypoxia concentrating on for mixed biotherapy and photothermal remedy. ACS Nano. 2018;12(6):5995–6005.
Gao J, Su Y, Wang Z. Engineering bacterial membrane nanovesicles for improved therapies in infectious ailments and most cancers. Adv Drug Deliv Rev. 2022;1(186):114340.
Han JW, Choi YJ, Cho S, Zheng S, Ko SY, Park JO, Park S. Lively tumor-therapeutic liposomal bacteriobot combining a drug (paclitaxel)-encapsulated liposome with concentrating on micro organism (Salmonella Typhimurium). Sens Actuators B Chem. 2016;1(224):217–24.
Ektate Ok, Munteanu MC, Ashar H, Malayer J, Ranjan A. Chemo-immunotherapy of colon most cancers with targeted ultrasound and Salmonella-laden temperature delicate liposomes (thermobots). Sci Rep. 2018;8(1):13062.
Park BW, Zhuang J, Yasa O, Sitti M. Multifunctional bacteria-driven microswimmers for focused lively drug supply. ACS Nano. 2017;11(9):8910–23.
Alapan Y, Yasa O, Schauer O, Giltinan J, Tabak AF, Sourjik V, Sitti M. Mushy erythrocyte-based bacterial microswimmers for cargo supply. Sci Robotic. 2018;3(17): eaar4423.
Quispe-Tintaya W, Chandra D, Jahangir A, Harris M, Casadevall A, Dadachova E, Gravekamp C. Unhazardous radioactive Listeriaat is a extremely efficient remedy in opposition to metastatic pancreatic most cancers. Proc Natl Acad Sci. 2013;110(21):8668–73.
Chandra D, Selvanesan BC, Yuan Z, Libutti SK, Koba W, Beck A, Zhu Ok, Casadevall A, Dadachova E, Gravekamp C. 32-Phosphorus selectively delivered by listeria to pancreatic most cancers demonstrates a robust therapeutic impact. Oncotarget. 2017;8(13):20729.
Fan JX, Peng MY, Wang H, Zheng HR, Liu ZL, Li CX, Wang XN, Liu XH, Cheng SX, Zhang XZ. Engineered bacterial bioreactor for tumor remedy by way of Fenton-like response with localized H2O2 era. Adv Mater. 2019;31(16):1808278.
Zheng JH, Nguyen VH, Jiang SN, Park SH, Tan W, Hong SH, Shin MG, Chung IJ, Hong Y, Bom HS, Choy HE. Two-step enhanced most cancers immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin. Sci Transl Med. 2017;9(376): eaak9537.
Nishikawa H, Sato E, Briones G, Chen LM, Matsuo M, Nagata Y, Ritter G, Jäger E, Nomura H, Kondo S, Tawara I. In vivo antigen supply by a Salmonella typhimurium kind III secretion system for therapeutic most cancers vaccines. J Clin Investig. 2006;116(7):1946–54.
Jiang SN, Park SH, Lee HJ, Zheng JH, Kim HS, Bom HS, Hong Y, Szardenings M, Shin MG, Kim SC, Ntziachristos V. Engineering of micro organism for the visualization of focused supply of a cytolytic anticancer agent. Mol Ther. 2013;21(11):1985–95.
MacDiarmid JA, Langova V, Bailey D, Pattison ST, Pattison SL, Christensen N, Armstrong LR, Brahmbhatt VN, Smolarczyk Ok, Harrison MT, Costa M. Focused doxorubicin supply to mind tumors by way of minicells: proof of precept utilizing canines with spontaneously occurring tumors as a mannequin. PLoS ONE. 2016;11(4): e0151832.
Solomon BJ, Desai J, Rosenthal M, McArthur GA, Pattison ST, Pattison SL, MacDiarmid J, Brahmbhatt H, Scott AM. A primary-time-in-human section I scientific trial of bispecific antibody-targeted, paclitaxel-packaged bacterial minicells. PLoS ONE. 2015;10(12): e0144559.
Sagnella SM, Yang L, Stubbs GE, Boslem E, Martino-Echarri E, Smolarczyk Ok, Pattison SL, Vanegas N, Clair ES, Clarke S, Boockvar J. Cyto-immuno-therapy for most cancers: a pathway elicited by tumor-targeted, cytotoxic drug-packaged bacterially derived nanocells. Most cancers Cell. 2020;37(3):354–70.
Sagnella SM, Trieu J, Brahmbhatt H, MacDiarmid JA, MacMillan A, Whan RM, Fife CM, McCarroll JA, Gifford AJ, Ziegler DS, Kavallaris M. Focused doxorubicin-loaded bacterially derived nano-cells for the therapy of neuroblastoma. Mol Most cancers Ther. 2018;17(5):1012–23.
Whittle JR, Lickliter JD, Gan HK, Scott AM, Simes J, Solomon BJ, MacDiarmid JA, Brahmbhatt H, Rosenthal MA. First in human nanotechnology doxorubicin supply system to focus on epidermal progress issue receptors in recurrent glioblastoma. J Clin Neurosci. 2015;22(12):1889–94.
Gujrati V, Prakash J, Malekzadeh-Najafabadi J, Stiel A, Klemm U, Mettenleiter G, Aichler M, Walch A, Ntziachristos V. Bioengineered bacterial vesicles as organic nano-heaters for optoacoustic imaging. Nat Commun. 2019;10(1):1114.
Carleton HA, Lara-Tejero M, Liu X, Galán JE. Engineering the sort III secretion system in non-replicating bacterial minicells for antigen supply. Nat Commun. 2013;4(1):1590.
Schetters ST, Jong WS, Horrevorts SK, Kruijssen LJ, Engels S, Stolk D, Daleke-Schermerhorn MH, Garcia-Vallejo J, Houben D, Unger WW, den Haan JM. Outer membrane vesicles engineered to specific membrane-bound antigen program dendritic cells for cross-presentation to CD8+ T cells. Acta Biomater. 2019;1(91):248–57.
Huang W, Shu C, Hua L, Zhao Y, Xie H, Qi J, Gao F, Gao R, Chen Y, Zhang Q, Li W. Modified bacterial outer membrane vesicles induce autoantibodies for tumor remedy. Acta Biomater. 2020;1(108):300–12.
Chen Q, Huang G, Wu W, Wang J, Hu J, Mao J, Chu PK, Bai H, Tang G. A hybrid eukaryotic–prokaryotic nanoplatform with photothermal modality for enhanced antitumor vaccination. Adv Mater. 2020;32(16):1908185.
Akin D, Sturgis J, Ragheb Ok, Sherman D, Burkholder Ok, Robinson JP, Bhunia AK, Mohammed S, Bashir R. Micro organism-mediated supply of nanoparticles and cargo into cells. Nat Nanotechnol. 2007;2(7):441–9.
Xie S, Zhao L, Music X, Tang M, Mo C, Li X. Doxorubicin-conjugated Escherichia coli Nissle 1917 swimmers to realize tumor concentrating on and responsive drug launch. J Management Launch. 2017;28(268):390–9.
Hu Q, Wu M, Fang C, Cheng C, Zhao M, Fang W, Chu PK, Ping Y, Tang G. Engineering nanoparticle-coated micro organism as oral DNA vaccines for most cancers immunotherapy. Nano Lett. 2015;15(4):2732–9.
Xie S, Chen M, Music X, Zhang Z, Zhang Z, Chen Z, Li X. Bacterial microbots for acid-labile launch of hybrid micelles to advertise the synergistic antitumor efficacy. Acta Biomater. 2018;15(78):198–210.
Suh S, Jo A, Traore MA, Zhan Y, Coutermarsh-Ott SL, Ringel-Scaia VM, Allen IC, Davis RM, Behkam B. Nanoscale bacteria-enabled autonomous drug supply system (NanoBEADS) enhances intratumoral transport of nanomedicine. Adv Sci. 2019;6(3):1801309.
Li Q, Chen H, Feng X, Yu C, Feng F, Chai Y, Lu P, Music T, Wang X, Yao L. Nanoparticle-regulated semiartificial magnetotactic micro organism with tunable magnetic second and magnetic sensitivity. Small. 2019;15(15):1900427.
Moreno VM, Álvarez E, Izquierdo-Barba I, Baeza A, Serrano-López J, Vallet-Regí M. Micro organism as nanoparticles provider for enhancing penetration in a tumoral matrix mannequin. Adv Mater Interfaces. 2020;7(11):1901942.
Zheng DW, Chen Y, Li ZH, Xu L, Li CX, Li B, Fan JX, Cheng SX, Zhang XZ. Optically-controlled bacterial metabolite for most cancers remedy. Nat Commun. 2018;9(1):1680.
Park W, Cho S, Huang X, Larson AC, Kim DH. Branched gold nanoparticle coating of clostridium novyi-NT spores for CT-guided intratumoral injection. Small. 2017;13(5):1602722.
Luo CH, Huang CT, Su CH, Yeh CS. Micro organism-mediated hypoxia-specific supply of nanoparticles for tumors imaging and remedy. Nano Lett. 2016;16(6):3493–9.
Dong H, Sarkes DA, Rice JJ, Hurley MM, Fu AJ, Stratis-Cullum DN. Residing micro organism–nanoparticle hybrids mediated by way of surface-displayed peptides. Langmuir. 2018;34(20):5837–48.
Dogra N, Izadi H, Vanderlick TK. Micro-motors: a motile micro organism primarily based system for liposome cargo transport. Sci Rep. 2016;6(1):29369.
Thamm DH, Kurzman ID, King I, Li Z, Sznol M, Dubielzig RR, Vail DM, MacEwen EG. Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to canines with spontaneous neoplasia: section I analysis. Clin Most cancers Res. 2005;11(13):4827–34.
Heimann DM, Rosenberg SA. Steady intravenous administration of dwell genetically modified salmonella typhimurium in sufferers with metastatic melanoma. J Immunother. 2003;26(2):179.
NCT00004216. ClinicalTrials.gov. http://www.clinicaltrials.gov/ct2/present/NCT00004216.
NCT00358397. ClinicalTrials.gov. http://www.clinicaltrials.gov/ct2/present/NCT00358397.
NCT01099631. ClinicalTrials.gov. http://www.clinicaltrials.gov/ct2/present/NCT01099631.
NCT01118819. ClinicalTrials.gov. http://www.clinicaltrials.gov/ct2/present/NCT01118819.
NCT01562626. ClinicalTrials.gov. http://www.clinicaltrials.gov/ct2/present/NCT01562626.
NCT01924689. ClinicalTrials.gov. http://www.clinicaltrials.gov/ct2/present/NCT01924689.